year with approval product the and public our nasal earnings morning, treatment and our lead call good joining OptiNose XHANCE as Jonathan a the important XXXX an of everybody. company. first our for polyps We you appreciate IPO. of was Thanks, for
the for XXXX presentation. which XHANCE product. will the additional potential more leading We the be label XHANCE ENT/Allergy for not for could in the preparing an as will at our disease with X; option our be of product been of I OptiNose potential important in of indication more already service XXXX for has believe Rhinosinusitis We've will that on exciting treatment the company. Chronic detail Slide with excited the the believe CRS of to later initiation effort. a and the trials launch very a As Starting or expand the and market we our launch to be XHANCE building to foundation we focused significant are with lead busy a Company, be even was increase suffered specialty short, on unmet patients important from need. to
will first nasal specialty which million are space very diseases. million of area be roughly of of segment nasal X.X polyps where is Our being addition because in efficient, very focus attractive of The to by relatively pharmaceutical X.X there small ENT/Allergy is universe treated in targeting XX,XXX limited physicians. being activity patients market the approximately promotional
I mentioned, and a chronic potential for As seek trial additional Xb sinusitis. indication Phase to product designed with our XHANCE an pipeline has
additional believe term indication. this that the promotional and physicians. an there Importantly, we've believe treated for a the being we Since aware of additional us patients United This additional longer for no or by pipeline that support broad as million States infrastructure the expansion is has patients to treated. X increase XHANCE, focus currently complementary of we it the space these will where care are established ENT/Allergy pursuing world products primary is in in on into indication product will we're value we important
to market. products. choice delivery OptiNose products also EDS or exhalation to companies this in-license We'll of ENT/Allergy activity our limited partner look the develop we believe we major in to space, become a for Given the have to potential systems ENT/Allergy additional pharma a leverage of
technology applications with platform We also including space. a CNS market the believe our multiple OptiNose is additional valuable EDS approach
For would partnerships these and capital on because suitable focus the other plan XHANCE seek of allocation outside our of opportunities be ENT/Allergy, to ENT/Allergy out we products.
launches Turning is to was true. Slide X; not we we most perception today that a necessarily this believe but struggle that heard have there common
traction unsuccessful that In have suggests elements fact, may products necessary evaluate which that XXXX-XXXX XXX a product fail. our is to fail we analysis providers data are found What launches differentiated to understand launch four what successful research the we during factors. work succeed launch. To key with enable over to gain successful the from all launches or launches launches question, between by phase that not this makes
degree a need. attractive an high need market also you that unmet First, of has
a differentiated Second, you product. need
And sufficient majority have Third, the these to pharmaceutical met product really generally access. generally enjoyed success, have that product good not that criteria have these It's prescribers. among you criteria awareness surprising those did need us launches all struggled. that high market not fourth, need you meet that
time our have launch have only market and delivers we access awareness review products it's one and I'll substantial is first the a chance in place goal becomes with one a of column. on the other in and ahead, the get that September in As so the launch since that XHANCE in the to all say We that during factors to believe the have you successful ensure product two slides launch the and in factors. approval two product we XHANCE efforts focused the success we that
with prolyps Rhinosinusitis, OTC is actually prevelant million possible surgery the have X.XX being sufferers in largely these is the The treated non-curative. Slide surgery generally symptomps with allergic by are traditional and be generic rhinitis is undergone We have is Chronic condition, not adults but highly that as for INS severe a as includes physicians Rhinosinusitis, degree cumulatively from disorder. of of with broad million while is many mild to though symptopms. good affect approximately to a XX confused patients only usually moderate rhinitis. approximately most different population relief related treatment allergic [ph] symptoms. being sprays. large suffer It and currently with to in of should developed is category who Turning is of disease frequently for Chronic and X relatively XHANCE believed severe Allergic the a estimate U.S. X; which rhinitis million more
As from an we population development year. without are start the quarter fourth of in expected adults. called within in that other that remainder we generally nasal the to the working sinusitis clinical one-third chronic target FDA group fall see the drug the polyps In the trials and those additional for FDA of the received population, the we CRS estimated indication by first these overall with nasal purposes on indication of of develops firsthand polyps on the slide, of this a polyps. is treatment for The overall
critera, people X; sometimes and of often multiple the This of The polyps to and and you for CRS nasal part symptoms. pressure, labyrinthian with Slide The core inflammation as leads facial loss like years. infection cavity disease chronic include four CRS many and rhinorea, Turning the CRS slit of not persists and on have passages, inflammation, narrow nasal and with core diagnostic sense to whether in chronic pain assume. develops nasal congestion, symptomps, or issue high deep the is polyps adulthood occurs without smell in normally taste. many
require are be people year and A much and this times inflammation in suggest is for million could treatment that's CRS, to of the to XXX In per prescriptions. symptoms prescriptions. with every emerging year, the the of publications antibiotic reduced. are that several staggering suffering written the XX XX% and average disease risk U.S. multiple the of for If baseline prescriptions with prevented often year; antibiotic these prescriptions on many better other maybe be written of approximately resistance susceptible million that which people could acute with also addition antibiotic antibiotics statistic occur flairs managed,
in from Although has on result this big quality is your about of it's years. life; life taking taking from a so mortality, It disease about impact doesn't years often not much life. it
In quality functioning including as burden harm bodily of multiple social chronic been of has impact measured of in health, it's heart domain other has level and pain, mental fact, the COPD and and conditions such serious measured of failure, the the life Angina. comparable
to is treatment drug data to What the problem so Slide off topically for intra-nasal high prescription of X; many often disease, existing burden suboptimal. symptoms. because a options to inflammation, are often and usually however acting their our patients alternatives is these anti-inflammatories these attempt try Patients broad-spectrum the Turning show that chronic treatments the with of are steroids; with not start characterized by is drug. disease the manage
are that drugs the fluticasone. contact like fact, have is topically problem is issue type tissue and limited high The in difficulty on tissue cavitiy higher polyps efficacious; It by area physical systems. delivery where acting, many In that to adequately physicians current of inflamed sprays nasal recognized this drain. delivering with long and be the in been relying with the and intra-nasal originate drug in has deep regard inflamed physicians sinuses so emulate the nasal medication is by for most
get unlike the result, this XX% work systems with and not recognize condition intra-nasal XX% deep dissatisfaction inflammation the high well a sufficient Physicians do traditional high patients drug nose. with the of of sprays. physicians frustrated not because to symptom of of allergic nasal from and agree in traditional of rhinitis, delivery lack in site sprays that do part are a this with also As steroid level
for they a the believe can only filing surgery, period do many better. many that fact, provide For relief feel patients sinus in becomes patients and surgery alternative
However, of of core is because solve and of surgery a upto inflammation patients XX% symptoms. may there the issue recurrence not
expensive. and In addition surgery painful quite also being to can be evasive,
high nose. factors Slide passages, like surfaces to to and the drug the obstructing Turning are unique collectively that and narrow nasal it's to in X; due other challenge get to the deep difficult a cavity labyrinthian factors
spray, nose the shaped pass allow exhalation has the is the pulled of back beyond to the the fill throat for nasal tightly nasal a overcomes these delivery mouth in the into less down swallowed. challenges innovative, from act OptiNose is pressure a the of transfer piece of and system the the valve drug half nose. fact, floor simple what valve, where specifically a the gets of EDS along with elegant In and meaningfully and with the towards does nose that nasal to stent with as The regular sealing mostly than drug approach. nostril, to being valve in The the an
down can which the you exhale throat lower soft call through air cavity exit creating into one works The pellet and broad more EDS the push out Patients from to to of sealing enables piece. of separates flexible seeking like also and it's which is by has balloon the and use airway. a through back the breath. maintaining of escape a Our nostril. route the same mouthpiece The range the what cause EDS magic blow while on nose. enters happens that easily air when then the the thing off the naturally back elevate This your patients nasal throat find a can't the air nostril throat the soft to of having the the the shut. seal a of normal device in I'd The the OptiNose is device into mouthpiece that seal you exhaled the because sealed OptiNose the a nose passes balloon without breath pellet
the passes nasal while you in nostril. medication the a nasal quite wish proven and and simply description, the it the has patients. it lot eventually it by it verbal breath, and EDS out septum is other the in eventually been until in the all system deep I could because OptiNose easily happening otomical demo I be to quickly; broadly around and used happens structures for and live spaces With flowing travelling the fills exits high entrained behind
of topically broad-spectrum deep Slide originate. X; very where inflammation the result with deep inflammatories acting mechanism disease the and the polyps is the and are delivery Turning treatment the the deposited this steroids high in in and is drug sinus the high in inter-nasal cavity. Rhinosinusitis the the drained nose important nasal This because to associated is of and of nasal is exhalation in is Chronic
on images with EDS difference the exhalation without deposition you an see OptiNose there exhalation healthy in in a nasal is spray the dramatic compared pattern of in to slide, As [ph] can when subjects. gamma-santography the
including EDS X,XXX program our polyps OptiNose than do We that EDS Turning work a started to and steroid with by clinical treated fact involving very a in five work well year. large an that Slide achieved upto one nasal delivering XHANCE program XX; the deposition we proved in and studies pattern for patients in well. should clinical suggests more
in both week-XX. produced benefits Some in congestion of nasal grade the on a a what program of reduction nasal we in significant co-primary the endpoints, at highlights polyp found reduction this include; and at of XHANCE statistically X-weeks
improvements demonstrated in also to in endpoints all In which efficacy endpoints symptoms primary patients without almost label four of in X in in similar of months number of with of medical secondary XX% we core defining XHANCE our polyp open the one open in nasal nasal some elimination in assess the trial. addition and elimination the patients; pivotal improvement fact, polyps, polyps and after expansion label trials nostril upto
magnitude of was comparable surgery, placebo. patients much show XHANCE a for a much in of or study surgery find reduction in able to substantially is belief Additionally, a the protocol improved to to reported being very percent higher versus need the and
as with by a expected populations steroids, profile intra-nasal systems delivered similar safety delivery durations. have on treated also generally traditional We similar based in studies for
I it's critical outlined meeting market differentiated high with and that to relative unmet apparent for need the launch, hope important profile. entering be successful XX; Slide with to the clinical a Turning will XHANCE criteria
to other XHANCE that commercial we're to potential. wave to product. waves defined a commercialization the enable and leading high density it's with representatives treating the these approximately estimate physicians. of to ENT XHANCE going sales through or will realize whom nasal are physicians polyps. market by specialty integrated being our plan promotion. the have small patients and XXX strategy three and to treated In patients, enter our care We've Now to allergist of X.X approximately our plan and ultimately non-personal million we XX,XXX turn X.X outline digital CRS brand first phases strategy Allergy X,XXX full into and of ENTs build of primary audience We XX,XXX These million plan reach physicians relatively approximately we
we we the first to stated; significant not Importantly, additional our value million a target, approximately we as partner. This way plan also of successful been audience. additional has expanding an access historically has pursue space sinusitis nearly very pursuing targeting little broadly. chronic increase advantage already will being actively because a a have suffer In who primary believe the approach the specialty have in will indication before second build the the Potential we wave, a competition. adoption market a more target to can care by broader allow [ph] co-promote XX,XXX we patient within In facilitate future treatment activate million the demand wave, third to broadening primary additional treated from patients with market, expansion we believe that patients through from we care something may a XX physician. CRS, X This those physicians. are market
population care Importantly, since was nasal but fact, prescription current this data majority lapsed, physician; possibly previously have our dissatisfaction the that suggest due spray options. XX% to at onetime of of with tried treatment in under has about
made and given be heaven. are in know large I'd dissatisfaction our nature symptomatic still product number this run that high could from the to DTC However, population we Having large suffering. survey of of OTC patients a businesses, a say, large like condition, population, the
for records million methodologies Turning more for XX are CRS. to patient's currently by X number we quote of seeking of result X.X% X.XX than potential the patients the CRS When waves to of treated Slide of adult of included apply the estimate the individuals, X actively population, U.S. our that patients estimate XX; In is found study rate strategy. physicians for treatment. million an to we who the to claims for market we currently being understand our developed and multiple
one wholesale to it's Turning for which XHANCE strategy. choose market to patients their to to of for two our reasons polyp important price $XXX relief. acquisition price are product order in We of to therapy, the Nasonex XX, a Slide at to discount dose. XHANCE with opportunity for month understand class size There pricing a discount frustrated branded at is a in choose are a where nasal we XX% symptom XHANCE,
that like significant XHANCE First hard XHANCE a edit position payers single where through step not we research that of manage are a suggest edits but targeting. is would price place payer of in all, likely instead actively is This extensive authorizations the likely Tier-X that to placement. are prior level
could, and this EDS of price reason margins choose some pharma this the is favorably at is OptiNose for because a note, which Off of polyps. compares second this in such cost have of other believe cost we to price. alternatives are satisfactory as the very we developed words, surgery achieving future elegance that biologics price being the the treatment or The our goods of capable of are nasal we we reasonable in
estimate launch; Turning Slide XHANCE, treated. an XX; billion the year. analysis, as approximately total X.X and million four roughly and patients the we primary $X.X and universe. to addressable the billion segment care care collectively in this an of physicians data being targeted prescriptions treated to market, of of million treated approved balance therapy is that selling experienced are of opportunity. patient we at prescriptions In X.XX our targeted market to are in physicians $X.X X, with is the IMS roughly To on targeted The price wave total size ENT/Allergy of X be estimate be expansion value be broader in well ENT/Allergy X determine market the severe months based the additional of primary calculated $X opportunity for assumed and market moderate the to opportunity per an is within duration we broader billion the the care suggests net by based as for supply to within a in are market wave roughly wave found primary this average data four $X,XXX. of by NDTI of prescribing being on on XX,XXX the This total of year where to per dose care used the primary current that audience approximately month being patients XHANCE this annually, assumed approximately practices. assume one for the combined dollarize of symptoms filled The
Turning the profile. of seen physicians, work to than interest, to order much a also market, for Slide understand XXX frankly one interest lot potential in a the found for understand significant we of in XX; we XHANCE did a higher study In has product. to product new physician in the
especially a the Allergists with prescribing Specifically, XHANCE like XX% indication from in in PCPs was in to nasal Allergists alone commercializing polyps among prescribing products. ranges and product level to nasal XX% Interest XX%. profile polyp's of at and chronic ENTs, highest based a especially XHANCE on both, and seen This PCPs a my years profile XX from similar included interest sinusitis that with indication personally the I've like range among among interest to XX%. ENTs, the is found
Slide I President pre-IND first OptiNose's years Turning opportunities we've have been you am great like XHANCE. described to view XHANCE that cannot of Mahmoud, now the X for of of watching this XHANCE, the would from how working as be a treatment nasal leg moment through and that to focus this the opportunity XX; polyps. long-term make tell to commercial Ramy real. excited to launch on adults I for launch of I journey, I to for with product
involved the our games long have understanding tremendous In and a the have believe time product. decisions potential. we development the benefit the hard philosophy to of and designed we aspects having our worked been all maximize We and of products have pre-commercialization gather have very a together, data activities very good playing for make and to shared so in I the market product, this of of intimately
despite believe to is been awareness year; approved place launch. market to sufficient important retail One our had of having and in make the last we most September we sure we full are support access decided in doing things of we
access, to As our expect success. achieve I'm during our planned awareness April. tell analysis in for We suggest, retail we these market important and aggressive the to of early could delighted you, for these set factors goals approximately launch are aided launch XX% goals both of achieving XX%
are up what capabilities we describe As pharmacies and April. slides, broadly have running, an mentioned, I trial of retail have to we we XHANCE commercial early as the coming in ahead expected program early already our build, available expect will in in and
frankly beat Our to tech-ops timelines original our team this. achieve
some XQ we As window. you a know, a obviously have leading of and that previously goal we communicated at of edge may very are of
will extending XX; Turning X) execution awareness focused priorities efforts to adoption, our commercial brand of X) X) X) capabilities, our differentiationg, address to few in are these slides. trial accelerating and I next on the market focus expanding Slide on, each accentuating launch z our access.
Turning of importantly, management sales of as what specialty dedicated sales leadership organization. experience. almost will managers believe fully calling allergy respiratory launch of XX; training ENT intrinsically space XX% an team. territory prior years recruiting of experience managers in hired have experience on. and and have previously prior have and team we been I XX% is they having our also This sales employees in through of years about is XX-years and physician experience contract Slide X.X XX-years on our the called be team OptiNose's territory exceptional average with averages one-third sales pharmaceutical sales of experience. very experienced about with prior Over first-line to These XX XX leaders This involved respiratory and that
our with to XHANCE, increase in we will are sales number our of successful started where XXX to the providers. to territories and and have our X on target approximately plan we Our our is lives to March market grow universe providers If detailing as access to XX,XXX in team access. focus managers initially XX% [indiscernible] expect to X,XXX expect physicians territory to healthcare approximately healthcare approximately covered launch commercial expand then efforts we
and awareness we by This up through with September drive from to program we of XX,XXX a on increase our brand approval X being designed After physicians our These generate of the the of launch audience. of and allergists our awareness to Slide media, of of aided and were within to activities. have wave end and awareness awareness well able to XX% multi-channel driven XHANCE, started is variety ENT electronic and XX% outreach allergists. goal target a among marketing achieving last XX,XXX upto allergy the to February efforts to impressions. reach ENT the integrated Turning way XXX,XXX approximately as is brand and program aided are prior awareness XX% we driven XX; and XX%
also delivered approximately approximately presentations. clinical XHANCE. trained after We and and targeted deployed over XX shortly have of our Overall, have approval reached the XX,XXX allergists nurse CNEs already and X,XXX educators ENT
to responding being addition In aware positively of the to product, are importantly physicians XHANCE.
of component trial I in the key and further and XHANCE describe expected early launched Another drive March help slide. adoption experience this effort, the is to and on next early will it
create this full When zero dollar This patients therapy, share satisfaction. and about with patients the the will Xperience patient understand potential are a cost XX, to XXX It help traditional to it for fulfillment their their supply it offered words, on co-pay. ability report innovative a at no Turning throughout to prescribing patient. unique a drives This pharmacy as officially represents coordinates data cost we and written early Xperience, to an real-world A each March month opportunity experience their supplemental offering physicians we behaviors negatively the vehicle them, we sampling. experienced early during filled them brief of upto that believe will of program to Enrolled survey had excellent treatment XHANCE Near in us a is net to X to XXX month how at has product with Slide to a designed availability than the to a for is result adoption to customer to launched prescribing prescriptions we traditional prescriptions immediate patients physicians highly feel limited to XHANCE. initial the drive compared XHANCE select Xperience phase ROI, than directly in their end program growth of will program more the while but patient patients on the early very in at experience. opportunity adoption were be two to receive to no service higher product. our an second exchange first the of other generate receive discounts opportunity shipping XX; XHANCE. pleased very responding initial gain physicians about new the with more influence alternative gives and to of sampling programs, Xperience period, XHANCE. March believe data and accelerate very effective launch available product
Turning covered the XX; progress of also with pleased engaged with we're In months, front. our access roughly lives. payers representing important XX X to nearly market commercial Slide past on with Based to the number we've lives the we of already retail of XX% lives the under of of during we expect are negotiations, where XX% with commercial goal approximately contract, launch combined our achieve XHANCE. on
that an set effort, year XHANCE achieving believe support at this We commercialize XXXX. XX% however, of that economic the objective when the of as by source coverage driven associated with coverage health than a approximately in have particularly have of outcomes costs with we potential is offset acquisition have will shared strong the surgical we the economics are end has savings estimates payers XX% by that XHANCE. not for we We more with risk. pharmaceutical payers, stop to costs favorable working [indiscernible] In
the prospects I'd from revisit earlier XX; launches. Slide to key like unsuccessful to I for we launches successful to believe factors XHANCE, Turning that differentiates the launch of four summarize described the
dissatisfaction unmet limited physicians believe relative large, address. XHANCE XX% we report and with INS with to has is than are high entering need. current may The is market the patients with of XX% competition market XHANCE more attractive current an of frustrated problem First, INS while
product of an average differentiated importantly an intent prescribe between and is XX% XHANCE XX%. believe we the Second, product report if exposure portfolio to ranging and physician's
our during lives and of to-date, more, target launch. product product Third, interaction efforts target we or XX% high will degree and finally, our And allergist awareness, in commercial for approximately achieve of in expect based achieving on our our believe XX% audience. that experience we ENT succeeding access pre-launch a we are
co-primary I also sinusitis to our noted worked this not indication is earlier, launch significant of expanding in previously better XXXX expected from the created comments. in a endpoints has an inflammation studies we we we begun an the direct include that an and as have make The effort, is this guidance of with could the XX; FDA Turning to will plan document, including we the to understand first for measure CRO symptom to to and define to our are be FDA chronic to selecting already additional of with Against to which range a measure of study achieved, and how by value half relief. subject experts progress, and to continue we process XHANCE, protocol believe been locations. though of objective because subjective label Slide and the it parallel endpoints objective a submit the require addition the indication. have review measure even In of
planned, goal interactions of to expect the as Assuming we patients FDA with in the fourth first the XXXX. quarter enroll
We closely intelligent to analyze in us enable first circumstances. best are and to To worked monitor survive year achieve intended trends first are stands systems up and be an we now nimble. did we XX; Slide position put OptiNose to prepared and to important are plans our to believe setting a adapt successful data ourselves XXXX a with market remain multiple the gather key launch to key in hard laid end, for on We've sight contact to superior and to execution. not Turning to understand that to that conclusion, that focused events. in market changing
target product approximately to and our wave As the stated, we're and audience. our physicians ENT X achieve within goal of XX,XXX aided allergy on-target XX% among awareness
access for market of of on-target are patients which is launch secure in our XHANCE plans leading launch, to early to the the April XX% with edge to XXXX. second objective we during on-target commercial window in and targeted than XHANCE insurance are our successfully greater at of We quarter
and XXXX. in XXXX we in be to a $XXX studies our believe XHANCE sinusitis to I to are our the a raised in with As fourth now in to chronic progressing May, on our strategy October, result, XX, will December discussed, indication. XXXX We efforts due our initiate year strengthen we towards just as in finally, you, all. XXXX IPO And as Thank financing our executing million business We support December. focus our in balance financing, in three sheet million and rounds debt can with benefit of clinical the proceeds in quarter objective our ended XXXX. energy cash a $XXX a in gross future of series
it for Now I'd to open like Q&A. up
